Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128a4 · Date: 11/20/2025 · State: KY
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
29,481
Total Claims
$2.9M
Drug Cost
895
Beneficiaries
$3,285
Cost/Patient
Risk Score Breakdown 49/100
Score components are additive. Read full methodology
Peer Comparison vs. 44,021 Emergency Medicine providers
-22%
Opioid rate vs peers
7.3% vs 9.4% avg
+765%
Brand preference vs peers
12.8% vs 1.5% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider appears on the federal OIG exclusion list, meaning they have been formally barred from participating in federal healthcare programs due to fraud, patient abuse, licensing issues, or other misconduct. The fact that they still appear in active prescribing data is a significant concern.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
7.3%
Opioid Rate
2,155
Opioid Claims
$57K
Opioid Cost
0.8%
Long-Acting Rate
Brand vs Generic
Brand: 3,747 claims · $2.3M
Generic: 25,435 claims · $608K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Deutetrabenazine | 160 | $586K |
| Paliperidone Palmitate | 58 | $193K |
| Semaglutide | 126 | $143K |
| Rivaroxaban | 287 | $114K |
| Fluticasone/Umeclidin/Vilanter | 133 | $100K |
| Aripiprazole | 33 | $88K |
| Apixaban | 197 | $85K |
| Fluticasone/Vilanterol | 132 | $60K |
| Sitagliptin Phosphate | 88 | $53K |
| Empagliflozin | 105 | $50K |
| Insulin Glargine,hum.Rec.Anlog | 139 | $47K |
| Cariprazine Hcl | 59 | $45K |
| Linagliptin | 110 | $45K |
| Linaclotide | 66 | $44K |
| Dupilumab | 11 | $42K |
Prescribing Profile
Patient Profile
67
Avg Age
58%
Female
1.54
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data